Proprietary lactic acid bacteria from Maypro achieves Non-GMO Project Verification
Maypro Group has announced that its proprietary strain of Lactobacillus acidophilus, L-92, is the first ingredient in its portfolio become Non-GMO Project Verified.
Photo © iStockphoto.com/mipan
Maypro Group (Purchase, NY) has announced that its proprietary strain of Lactobacillus acidophilus, L-92, is the first ingredient in its portfolio become Non-GMO Project Verified.
“We are really excited to have one of our ingredients become part of the Non-GMO Project Verified portfolio” said Steve Yamada, Maypro Group’s founder and chairman, in a press release. “We hope that we can continue verifying our line of ingredients.”
L-92 is supported by five published double-blind placebo-controlled human clinical studies in both children and adults, and shows promise as a medical food, shown in human clinical studies to help with the dietary management of patients with psoriasis, allergic rhinitis, and cedar pollinosis. These studies have shown that L-92 may soothe and calm irritated skin, reduce redness and swelling, as well as reduce seasonal discomforts.
Magnesium L-threonate, Magtein, earns novel food authorization in the European Union
December 19th 2024According to the announcement, the authorization is also exclusive to AIDP and its partner company and licensee, ThreoTech, meaning that they are the only parties that can market magnesium L-threonate in the EU for a period of five years.
